Sumitomo Pharma America
NEWS
It was a particularly busy week for clinical trial news, in part because of several big medical conferences. Here’s a look.
There was a fair amount of clinical trial news last week. Here’s a look.
Myovant Sciences and Pfizer announced positive results from the Phase III LIBERTY trial of relugolix combination therapy in women with uterine fibroids.
Clarivate published its annual “Drugs to Watch” list, and cited four drugs that it expects to be blockbusters—projected to bring in $1 billion in sales annually.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Dr. Lynn Seely bows out as Myovant pivots to commercialize new drug.
Myovant Sciences’ stock rocketed 22% on news it was partnering with Pfizer to develop and commercialize relugolix for prostate cancer and women’s health.
The U.S. Food and Drug Administration has approved several drugs and medical devices in the last week. Here’s a look.
Myovant’s oral Orgovyx beat out Abbvie’s injectable Lupron in achieving medical castration levels in patients. Here is the timeline of the approval.
JOBS
IN THE PRESS